Scalable markers for early cognitive decline: Plasma p‐tau217, subjective cognitive concerns, and digital testing: Results from the A4/LEARN studies
Babak Khorsand, Devin Teichrow, Elham Ghanbarian, Lukai Zheng, S. Ahmad Sajjadi, Crystal M. Glover, Joshua D. Grill, Laura A. Rabin, Ali Ezzati · 2026
Read Scalable markers for early cognitive decline: Plasma p‐tau217, subjective cognitive concerns, and digital testing: Results from the A4/LEARN studies by Babak Khorsand, Devin Teichrow, Elham Ghanbarian, Lukai Zheng, S. Ahmad Sajjadi, Crystal M. Glover, Joshua D. Grill, Laura A. Rabin, Ali Ezzati (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13240426.txt.
Description
Babak Khorsand and co-authors test cheap, scalable markers for early decline in thinking, in a study from 2026. Brain scans and spinal fluid tests can confirm Alzheimer's disease, but they are too costly for mass screening. The team looked at three lighter tools: a blood marker of tau protein, a self-report of memory worries, and a computer test battery. Data came from two large studies of older adults.
The group covered 1,064 adults aged sixty-five to eighty-five who still thought clearly at the start. Over about four and a half years, a third of them slipped into impairment. Each of the three tools, on its own, flagged who was more likely to slip. Higher blood marker levels and more self-reported worries both raised the odds. The authors say the trio can enrich trials and sort risk without scans.
Catalog record
| CREATOR | Babak Khorsand, Devin Teichrow, Elham Ghanbarian, Lukai Zheng, S. Ahmad Sajjadi, Crystal M. Glover, Joshua D. Grill, Laura A. Rabin, Ali Ezzati |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 48 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |